These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37684380)

  • 21. [Clinical study of non-alcoholic fatty liver disease and its combined the chronic HBV infection].
    He J; Zeng YL; Li W; Guo EE; Li JL; Kang Y; Shang J
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):618-622. PubMed ID: 29056013
    [No Abstract]   [Full Text] [Related]  

  • 22. [The evaluation value of transient elastography for liver characteristics in obese children].
    Zeng FS; Yang HM; Gong Y; She LH; Li XF; Xu Y
    Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(40):3164-3168. PubMed ID: 33142400
    [No Abstract]   [Full Text] [Related]  

  • 23. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients.
    Singh A; Le P; Lopez R; Alkhouri N
    Hepatol Int; 2018 Jan; 12(1):37-43. PubMed ID: 29318450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD.
    Petta S; Wong VW; Cammà C; Hiriart JB; Wong GL; Vergniol J; Chan AW; Di Marco V; Merrouche W; Chan HL; Marra F; Le-Bail B; Arena U; Craxì A; de Ledinghen V
    Aliment Pharmacol Ther; 2017 Sep; 46(6):617-627. PubMed ID: 28752524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD.
    Xun YH; Guo JC; Lou GQ; Jiang YM; Zhuang ZJ; Zhu MF; Luo Y; Ma XJ; Liu J; Bian DX; Shi JP
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):643-9. PubMed ID: 24837195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-invasive Screening of Metabolic Associated Fatty Liver Disease and Affecting Factors in Primary Care.
    Balci IC; Haciagaoglu N; Oner C; Cetin H; Simsek EE
    J Coll Physicians Surg Pak; 2023 Apr; 33(4):390-395. PubMed ID: 37190709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study on the diagnostic value of transient elastography, APRI and FIB-4 for liver fibrosis in children with non-alcoholic fatty liver disease].
    He SL; Li SJ; Liu M; Ouyang WX; Chen WJ; Zheng X; Jiang T; Tan YF; Kang Z; Qin XM; Yu Y
    Zhonghua Gan Zang Bing Za Zhi; 2022 Jan; 30(1):81-86. PubMed ID: 35152674
    [No Abstract]   [Full Text] [Related]  

  • 30. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Cao YT; Xiang LL; Qi F; Zhang YJ; Chen Y; Zhou XQ
    EClinicalMedicine; 2022 Sep; 51():101547. PubMed ID: 35844772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality.
    Unger LW; Forstner B; Muckenhuber M; Scheuba K; Eigenbauer E; Scheiner B; Pfisterer N; Paternostro R; Trauner M; Mandorfer M; Reiberger T
    Dig Dis Sci; 2020 Sep; 65(9):2712-2718. PubMed ID: 31875288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients.
    Singh A; Le P; Peerzada MM; Lopez R; Alkhouri N
    J Clin Gastroenterol; 2018 Mar; 52(3):268-272. PubMed ID: 28787358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
    Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity.
    Coccia F; Testa M; Guarisco G; Bonci E; Di Cristofano C; Silecchia G; Leonetti F; Gastaldelli A; Capoccia D
    Endocrine; 2020 Mar; 67(3):569-578. PubMed ID: 31858390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver stiffness measurement by magnetic resonance elastography is not affected by hepatic steatosis.
    Chen J; Allen AM; Therneau TM; Chen J; Li J; Hoodeshenas S; Chen J; Lu X; Zhu Z; Venkatesh SK; Song B; Ehman RL; Yin M
    Eur Radiol; 2022 Feb; 32(2):950-958. PubMed ID: 34432123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accuracy of FibroTouch in assessing liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus.
    Yu H; Liu H; Zhang J; Jia G; Yang L; Zhang Q; Li G; Liu F; Di F; Wang F
    Ann Palliat Med; 2021 Sep; 10(9):9702-9714. PubMed ID: 34628896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study.
    Tutunchi H; Naeini F; Ebrahimi-Mameghani M; Mobasseri M; Naghshi S; Ostadrahimi A
    Int J Clin Pract; 2021 Jun; 75(6):e14131. PubMed ID: 33683797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Free Triiodothyronine Is Associated With Hepatic Steatosis and Liver Stiffness in Euthyroid Chinese Adults With Non-Alcoholic Fatty Liver Disease.
    Guo W; Qin P; Li XN; Wu J; Lu J; Zhu WF; Diao QQ; Xu NZ; Zhang Q
    Front Endocrinol (Lausanne); 2021; 12():711956. PubMed ID: 34456869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triglyceride glucose-waist circumference: the optimum index to screen nonalcoholic fatty liver disease in non-obese adults.
    Li S; Feng L; Ding J; Zhou W; Yuan T; Mao J
    BMC Gastroenterol; 2023 Nov; 23(1):376. PubMed ID: 37919650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of integrase inhibitors on steatosis and fibrosis biomarkers in persons with HIV naïve to antiretroviral therapy.
    Fernandes SR; Leite AR; Lino R; Guimarães AR; Pineiro C; Serrão R; Freitas P
    BMC Infect Dis; 2023 Aug; 23(1):553. PubMed ID: 37620821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.